fashion -WSS

fashion

author：fashion 2025-10-02 17:22:28 - browse：1285

Adobe

The Food and Drug Administration has cleared Otsuka Pharmaceutical’s digital treatment for major depressive disorder, offering a new option for millions of people who struggle with the stubborn mental health condition.

Called Rejoyn, the smartphone-based treatment for major depressive disorder symptoms was developed with digital health company Click Therapeutics, and it is intended for use by prescription alongside antidepressants. The six-week program delivers a novel “cognitive-emotional training” technique, in which people are asked to identify and recall faces showing different emotions. Researchers hypothesize that the technique targets the brain’s dorsolateral prefrontal cortex and the amygdala and may “enhance cognitive control over emotional information processing.” Patients also receive cognitive behavioral therapy.

Rejoyn has been in development since 2018, and Otsuka is the first drug company to receive FDA clearance for a digital treatment for a mental health condition. But that landmark comes amid many questions about whether such digital therapeutics deliver their advertised results — and whether they can gain traction with clinicians, insurers, and patients. Prescription digital therapeutics have yet to see a blockbuster success, and several companies have gone out of business trying to create one.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： The haunting brain science of long Covid

WSS

A new crop of companies is reshaping the health data economy

Biden warns of ‘dark winter’ during final presidental debate

US judge blocks portions of new Florida elections law

Some in Scotland's Orkney Islands want to return to Norway after 550 years

Legitimacy of 'customer' in Supreme Court gay rights case raises ethical, legal flags

The Democratic Party promised to overhaul its primaries. Doing that has been anything but simple

focus

fashion

leisure time

Peter Hotez and the public health issue of online harassment

Masked assailants attack a journalist and a lawyer in Russia's Chechnya province

Walensky prepares to leave CDC — and Congress — behind

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

United colonoscopy coverage change 'may cost lives,' doctors say

The haunting brain science of long Covid

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Ukraine holds disaster drills amid fears Russia could sabotage nuclear power plant

The high cost of giving birth even with insurance

UHS says company favors patients whose insurance pays more

leisure time

Roche’s Alnylam deal shows drug firms interested in heart drugs

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

ThunderShirts, dance parties and anxiety meds can help ease dogs' July Fourth dread

Elon Musk announces 'temporary limits' for reading Twitter posts

3 killed, 8 injured in late

Will the FTC rein in IQVIA's health data empire?

knowledge

focus

Wikipedia

focus